Compare Amphastar Pharmaceuticals Inc (AMPH) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Franklin Resources, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Franklin Resources, Inc. trades at $33.59 (market cap $17.41B). The key difference: Franklin Resources, Inc. is far larger — about 21.1× Amphastar Pharmaceuticals Inc's market cap, and Franklin Resources, Inc. pays a 3.94% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BEN | |
|---|---|---|
Market Cap | $826.08M | $17.41B |
Sector | Health | Financials |
52-Week High | $30.81 | $34.44 |
52-Week Low | $16.87 | $21.18 |
Enterprise Value | $1.22B | $29.23B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Franklin Resources (BEN) trades at $33.50, down 0.53% on the day, with a bullish technical outlook from moving averages and a consensus price target of $34.17. The company reported Q1 2026 EPS of $0.71, beating expectations of $0.55, and maintains strong profitability with an 80.72% gross margin. Recent news highlights its inclusion in dividend stock lists and a Zacks upgrade to Strong Buy on June 23, 2026, amid steady asset growth to $1.79 trillion AUM in June.
BEN presents a mixed outlook with solid earnings beats and dividend appeal offset by weak cash flow trends and modest growth. Upside is supported by analyst optimism and technical momentum, but risks include net cash outflows and competitive pressures in asset management. The stock's valuation at a P/E of 25.57 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
